FDA has approved Bayer's Kerendia to reduce disease progression risk in adults with chronic kidney disease associated with type 1 diabetes.

Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance, touches on what he sees as the most realistic path to making MFN pricing permanent.

Inizio's Elaine Ferguson on how cross-functional leadership pods tackling real business challenges are turning talent development into operational innovation.

Joe Cunningham argues that the most-favored-nation drug pricing agreements carry no legislative weight and discusses what the program actually locks in.

Inizio's Elaine Ferguson on why AI value requires deconstructing workflows task by task — aligning each to the right combination of talent and technology.

Pharma brands with all the right information are still invisible to AI — and why silence is the bigger risk than inaccuracy.

Dr. Elena Christofides on why cortisol dysregulation may be the hidden reason GLP-1s fail — and what to do when patients don't respond.

Inizio's Elaine Ferguson on why connecting talent across 10,500 employees and four business units is fundamental to delivering client value.